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A B S T R A C T
BACkgRound: Emerging evidence suggests that a strong link exists between certain 
liver enzymes such as γ-glutamyltransferase (γ-GT) and alanine transaminase (ALT) 
and cardiovascular diseases independently of alcohol intake. Elevated levels of γ-GT 
and ALT within normal values are considered as markers of inflammation and oxida-
tive stress independent of the metabolic syndrome.
oBjeCTive: This pilot observational study was conducted to evaluate serum levels of 
γ-GT and ALT within normal values in different atrial fibrillation (AF) populations.
MeThodS: Consecutive patients with AF and healthy control subjects were screened. 
Clinical and echocardiographic characteristics were carefully recorded. In each par-
ticipant, serum levels of γ-GT and ALT along with conventional inflammatory mark-
ers were determined. The final study population consisted of 81 patients with parox-
ysmal AF, 45 patients with persistent AF, and 39 control subjects.
ReSulTS: Serum γ-GT levels within normal values were significantly elevated in pa-
tients with paroxysmal (30.40±12.34 U/L) and persistent AF (38.38±18.11 U/L) in 
relation to control population (24.03±11.73 U/L) (p<0.001). Of note, γ-GT concen-
tration was significantly higher in patients with persistent AF compared to those with 
paroxysmal AF (p = 0.010). Serum ALT levels were significantly higher in patients 
with paroxysmal (27.51±10.23 U/L) and persistent AF (28.73±9.34 U/L) compared 
to controls (20.26±9.34 U/L) (p<0.001). In multinomial logistic regression analysis, 
the relative risk ratio of developing paroxysmal AF per 1 U/L increase in ALT was 
1.08 (CI: 1.02-1.14, p: 0.011). The relative risk ratio of having persistent AF per 1 U/L 
increase in γ-GT was 1.06 (CI: 1.01-1.12, p = 0.013).
ConCluSion: This study shows an association between increased levels within nor-
mal reference intervals of liver enzymes such as γ-GT and ALT and AF. Serum γ-GT 
levels may be related to AF burden. Larger studies are needed to examine this poten-
tial association.
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i n T R o d u C T i o n
Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia in clinical practice and contributes to im-
paired quality of life and increased morbidity and mortality.1-3 
The pathogenesis of AF is associated with the development 
of an appropriate atrial substrate related to abnormalities in 
atrial architecture such as atrial dilatation, fibrosis, apoptotic 
phenomena, and tissue dedifferentiation.4-6 Accumulating data 
suggest that inflammation and oxidative stress play a pivotal 
role in the genesis and perpetuation of AF.7 Atrial biopsies 
taken from patients with AF have demonstrated evidence of 
inflammatory infiltrates compared with healthy individuals, a 
fact that strongly supports the hypothesis that ongoing inflam-
mation may lead to structural remodeling of the atria, and thus 
to promote the perpetuation of AF.8 In atrial myocardium 
during AF, there is substantial oxidative damage that may 
contribute to atrial remodeling. Oxidative stress results from 
excessive reactive oxygen species (ROS), which are involved in 
pathological processes such as DNA damage, apoptosis, and 
cellular hypertrophy as well as signal pathway modulation.9 
Increased oxidative stress also underlies the early electrophysi-
ological remodeling associated with AF.7 Elevated levels of 
several markers of the inflammatory cascade and oxidative 
stress have been reported in different AF populations.10
Emerging evidence suggests that a strong link exists 
between certain liver enzymes such as γ-glutamyltransferase 
(γ-GT) and alanine transaminase (ALT) and cardiovascular 
diseases, independently of alcohol intake.11,12 Elevated serum 
levels of γ-GT and ALT within normal values are considered 
as markers of inflammation and oxidative stress independ-
ent of metabolic syndrome.13 Serum levels of γ-GT and ALT 
have never been studied before in patients with AF. This 
pilot observational study was conducted to evaluate serum 
levels of γ-GT and ALT within normal values in different AF 
populations including patients with paroxysmal and persistent 
AF. Any relationship with known conventional markers of 
inflammation and oxidative stress including high sensitivity 
C-reactive protein (hs-CRP), white blood cell (WBC) count, 
fibrinogen and uric acid was also investigated.
M e T h o d S
PA T i e n T S
In this cross-sectional study, we recruited consecutive 
patients with AF, either paroxysmal or persistent, who were 
seen at the emergency department or at the outpatient clinic 
of our hospital. The arrhythmia classification (paroxysmal 
and persistent AF) was based on the current AHA/ACC/ESC 
guidelines.14 Paroxysmal AF was defined as a self-terminating 
arrhythmia lasting less than 7 days. An arrhythmic episode 
lasting longer than 7 days or requiring termination by cardio-
version, either with drugs or by direct current cardioversion, 
was designated as persistent AF. All baseline demographic 
and clinical characteristics were carefully recorded. Patients 
with valvular heart diseases, thyroid dysfunction, renal failure, 
hepatic failure, active inflammation, malignancies, infections, 
alcohol or drug addiction and administration of drugs or 
supplements with anti-inflammatory or antioxidant action, 
apart from statins, were excluded from the study. Of note, all 
subjects included in this study displayed serum concentration 
of liver enzymes within normal values. Control patients were 
identified at the outpatient clinic during the same time period 
and recruited according to the same eligibility and ineligibility 
criteria, with the exception that control patients were free of 
current AF and any history of AF. 
e C h o C A R d i o g R A P h i C  S T u d y
Comprehensive transthoracic M-mode, 2-D scans and 
Doppler recordings were obtained in parasternal and apical 
views in all patients and controls using the Vivid-7 system 
equipped with a 2.4 MHz transducer (GE Medical Systems, 
Milwaukee, WI, USA). Left ventricular ejection fraction 
(LVEF) was estimated using the Simpson’s method (four-
chamber apical view). Left ventricular end-diastolic (LVEDD) 
and end-systolic (LVESD) diameters as well as end-systolic 
anteroposterior left atrial (LA) diameter (LAD) were deter-
mined in parasternal long-axis view. All measurements were 
averaged for 3 cardiac cycles.
B l o o d  S A M P l e S
Blood samples were obtained from all patients in the 
fasting state. The WBC count in the peripheral blood was 
determined by an automated cell counter (Sysmex NE 
9000). Serum levels of CRP were measured using a high-
sensitivity latex particle-enhanced immunoassay on a Hitachi 
717 automated analyzer (Tina-quant CRP detection, Roche 
Diagnostics). The precision of the assay calculated by the 
intra-assay and inter-assay coefficient of variation was <7%, 
the sensitivity of the method was 0.1 mg/dl and the detection 
limit was 0.3 mg/dl. Plasma fibrinogen levels were determined 
by the modified Claus method using the Multifibren U rea-
gent (BCS analyzer; Dade-Behring). Serum uric acid levels 
were determined through uricase enzymatic method (Roche 
Diagnostics). Serum ALT (normal values <45 U/L)15 and 
γ-GT levels (normal values <50 U/L in men and <40 U/L in 
woman)16 were measured using an enzymatic reaction with a 
Hitachi 717 automated analyzer (Roche Diagnostics).
S T A T i S T i C A l  A n A ly S i S
Continuous variables are presented as mean values + 
SD, whereas categorical ones are presented as absolute and 
relative frequencies (percentages). Differences in quantitative 
characteristics between groups were evaluated using one-way 
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analysis of variance (ANOVA) or Student’s t-test, depend-
ing on the number of the groups compared. Pearson’s χ2 test 
was used in order to test for any associations between two 
categorical variables. Correlations among study parameters 
were sought using the Spearman’s rho test. Forward model 
building procedure was used in order to select the model with 
the best predictive value during multinomial logistic regression 
analysis. The three categories of the dependent categorical 
variable were paroxysmal AF, persistent AF and controls. All 
reported p values are based on two-sided tests and compared to 
a significance level of 0.05. Data were analyzed using STATA™ 
statistical software (Version 9.0, Stata Corporation, College 
Station, TX, USA). The study was approved by the local review 
committee and patients gave their written informed consent 
to take part in the study.
R e S u l T S
The final study population consisted of 81 patients with 
paroxysmal AF, 45 patients with persistent AF and 39 controls. 
Table 1 shows the clinical, echocardiographic and laboratory 
data of the study groups. There were no significant differences 
among study groups regarding age, sex, incidence of hyper-
tension and coronary artery disease, statins use, WBC count, 
fibrinogen levels and hs-CRP levels (p >0.05). Subjects with 
AF, either paroxysmal or persistent, displayed higher body 
mass index (BMI) (p = 0.001), increased LVEDD (p = 0.002) 
and LAD (p <0.001), and increased levels of uric acid (p = 
0.002), ALT (p <0.001), and γ-GT (p <0.001) compared with 
the control population. Furthermore, patients with persistent 
AF exhibited decreased LVEF (p = 0.002) and increased 
LVESD (p = 0.004) in relation to controls.
Serum γ-GT levels within normal values were significantly 
elevated in patients with paroxysmal AF (30.40±12.34 U/L) 
and persistent AF (38.38±18.11 U/L) in relation to control 
population (24.03±11.73 U/L) (p <0.001). In particular, 
γ-GT concentration was significantly higher in patients with 
persistent AF compared to paroxysmal AF (p = 0.010). Se-
rum γ-GT levels were significantly correlated with LVEDD 
(rho = 0.160, p = 0.040), LAD (rho = 0.166, p = 0.033), age 
(rho = 0.188, p = 0.016), BMI (rho = 0.249, p = 0.001), and 
TABle 1. Clinical, Echocardiographic, and Laboratory Characteristics of the Study Groups
Control
(n=39)
PAF
(n=81)
PersAF 
(n=45)
PAF vs. 
Control
p value
PersAF vs. 
Control
p value
PAF vs. 
PersAF
p value
overall
p value
Age (years) 52.51 ±10.69 55.42±9.01 54.42±9.23 0.122 0.382 0.556 0.294
Sex (males) (%) 13 (33.3) 25 (30.9) 12 (26.7) 0.785 0.505 0.620 0.793
CAD (%) 0 (0) 3 (2.5) 2 (6.7) 0.454 0.245 0.348 0.189
Hypertension (%) 10 (25.6) 13 (16) 8 (17.8) 0.211 0.381 0.803 0.443
AF duration (years) - 5.90±3.04 4.96 ±2.81 - - 0.093 0.093
BMI (Kg/m2) 24.31±3.73 25.98±3.41 27.15±2.81 0.016 <0.001 0.053 0.001
Number of AADs (n) - 3.15±1.11 3.00±.90 - - 0.430 0.430
Statins (%) 7 (17.9) 15 (18.5) 9 (20) 0.940 0.811 0.839 0.968
LVEF (mm) 60.54±5.56 60.05±7.90 55.07±9.76 0.695 0.002 0.002 0.001
LVEDD (mm) 48.31±4.96 50.83±5.53 52.22±4.24 0.017 <0.001 0.145 0.002
LVESD (mm) 30.95±4.94 31.77±6.52 34.09±4.86 0.490 0.004 0.039 0.030
LAD (mm) 34.90±4.01 39.12±4.79 42.51±5.69 <0.001 <0.001 0.001 <0.001
WBC (mm3) 6645.90±1173.50 6153.33±1362.89 6438.44±1428.50 0.055 0.473 0.271 0.150
Fibrinogen (mg/dl) 336.74±98.40 316.20±79.89 317.20±67.37 0.260 0.299 0.943 0.403
Uric acid (mg/dl) 4.72±1.17 5.65±1.38 5.49±1.42 <0.001 0.010 0.527 0.002
hs-CRP (mg/dl) 0.34±0.10 0.37±0.26 0.43±0.31 0.512 0.080 0.265 0.256
ALT (U/L) 20.26±9.34 27.51±10.23 28.73±9.34 <0.001 <0.001 0.509 <0.001
γ-GT (U/L) 24.03±11.73 30.40±12.34 38.38±18.11 0.008 <0.001 0.010 <0.001
AADs = antiarrhythmic drugs; ALT = alanine aminotransferase; BMI = body mass index; γ-GT = gamma-glutamyltransferase; CAD = coronary 
artery disease; hs-CRP = high sensitivity-C-reactive protein; LAD = left atrial diameter; LVEF = left ventricular ejection fraction; LVEDD = 
left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic diameter; PAF = paroxysmal atrial fibrillation; PersAF = persistent 
atrial fibrillation; WBC = white blood cells.
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uric acid levels (rho = 0.201, p <0.0001). Serum ALT levels 
were also significantly higher in patients with paroxysmal 
AF (27.51±10.23 U/L) and persistent AF (28.73±9.34 U/L) 
compared to control subjects (20.26±9.34 U/L) (p <0.001). 
ALT was significantly correlated with LVEDD (rho = 0.174, 
p = 0.025), LAD (rho = 0.206, p = 0.008), and uric acid levels 
(rho = 0.20, p = 0.001).
As shown in Table 2, in multinomial logistic regression 
analysis, the relative risk ratio of having paroxysmal AF per 
1 U/L increase in ALT was 1.08 (CI: 1.02-1.14, p = 0.011), 
after adjustment for the effect of age, sex, BMI, statin use, 
and LAD. The relative risk ratio of having persistent AF per 
1 U/L increase in γ-GT was 1.06 (CI: 1.01-1.12, p = 0.013). 
d i S C u S S i o n
The main findings of the present study include the fol-
lowing: i. serum γ-GT and ALT levels within the normal 
reference intervals are significantly elevated in patients with 
paroxysmal and persistent AF; ii. an increase in ALT levels 
was significantly associated with paroxysmal AF development; 
and iii. an increase in γ-GT levels was significantly associated 
with development of persistent AF.
Increased levels of the liver enzymes, γ-GT and ALT, 
have been found to be associated with diabetes, cardiovas-
cular risk factors and components of the insulin resistance 
syndrome, even within normal reference intervals.11,12,16 γ-GT 
is mainly produced in the liver. Serum levels of γ-GT are 
determined by several factors, such as alcohol intake, body 
fat content, plasma lipid/lipoproteins and glucose levels, and 
various medications.17 γ-GT play a pivotal role in maintain-
ing intracellular antioxidant defense systems through its 
mediation of extracellular glutathione transport into most 
types of cells. Free radical production leads to depletion of 
glutathione, induces the expression of γ-GT and subsequently 
elevates serum activity of γ-GT. An increase in γ-GT activity 
can basically be a response to oxidative stress, and increased 
serum concentrations of γ-GT may identify people with a 
low-grade yet persistent increase of oxidative and other cel-
lular or systemic stresses.18,19 Increasing data are available 
about the associations between γ-GT levels and markers of 
oxidative stress (directly with F2-isoprostanes, an oxidative 
damage product of arachidonic acid; inversely with serum 
and dietary antioxidant vitamins), suggesting that the strong 
associations between cardiovascular risk factors might be 
explained by some oxidative mechanism.20-22
Accumulating data links oxidative stress with the patho-
genesis of electrophysiological and structural remodeling 
processes that perpetuate AF.1 In a recent study, Kim et al 
measured nicotinamide adenosine dinucleotide phosphate 
(NADPH)-stimulated superoxide production in right atrial 
appendage samples from 170 consecutive patients under-
going coronary artery bypass surgery. These investigators 
found that patients who developed AF after surgery had a 
significant increase in atrial NADPH oxidase activity than 
patients who remained in sinus rhythm, and increased atrial 
NADPH oxidase activity was independently associated with 
an increased risk of post-operative AF.23 More recently, 
clinical studies have shown that oxidative stress markers are 
increased in AF, and are associated with the presence of 
AF. In a cross-sectional case-control design study, Neuman 
et al showed that oxidative stress markers were significantly 
elevated in persistent AF patients, and oxidative stress but 
not inflammatory markers were associated with AF.24 In ad-
dition, Ramlawi et al investigated oxidative stress markers in 
patients undergoing coronary artery bypass grafting or valve 
procedures. They found that patients with post-operative AF 
had significantly higher serum peroxide levels compared to 
patients in sinus rhythm 6 hours following the procedure.25 
Furthermore, drugs that have antioxidant properties such 
as steroids and vitamin C show beneficial effects on AF 
development.26,27 In our study, γ-GT levels were significantly 
higher in patients with persistent AF compared with those 
with paroxysmal AF and the control population, an event 
possibly linked to the AF burden. For one unit increase in 
γ-GT levels, the relative risk of having persistent AF was in-
creased 6%, after adjustment for the effect of several factors 
including BMI. In addition, γ-GT levels were significantly 
correlated with LAD, indicating a possible role in left atrial 
structural remodeling. 
ALT has been less validated as a potential cardiovascular 
risk marker.28 ALT is often used in epidemiological studies 
as a surrogate marker for non-alcoholic fatty liver disease. 
In addition, recent prospective epidemiological studies have 
demonstrated that ALT is associated with future risk of type 
2 diabetes mellitus and the metabolic syndrome.29 A meta-
analysis that examined the association of ALT with incident 
cardiovascular events found a hazard ratio of 1.18 (95% CI: 
TABle 2. Multinomial Logistic Regression Analysis Show-
ing the Relative Risk Ratio of AF Development Based on 
γ-GT and ALT Serum Levels
variable
Relative 
Risk Ratio
(RRR)
95% 
Confidence 
intervals p value
PAF vs. Controls
γ-GT (per 1 U/L increase) 1.01 0.97-1.05 0.683
ALT (per 1 U/L increase) 1.08 1.02-1.14 0.011
PersAF vs. Controls
γ-GT (per 1 U/L increase) 1.06 1.01-1.12 0.013
ALT (per 1 U/L increase) 1.02 0.96-1.09 0.514
Abbreviations as in Table 1. 
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0.99, 1.41) for coronary heart disease and a hazard ratio of 
1.10 (95% CI: 0.89, 1.36) for coronary artery disease or stroke 
(combined).11 yamada et al have shown that elevated serum 
ALT levels were related to increased plasma levels of CRP 
and lipid peroxides.13 We showed that serum ALT levels 
were significantly elevated in patients with paroxysmal and 
persistent AF compared to controls. ALT was also significantly 
correlated with LAD. For one unit increase in ALT levels, the 
relative risk of having paroxysmal AF was increased 8%, after 
adjustment for the effect of several factors.
l i M i T A T i o n S 
Our study has some potential limitations. First, the number 
of participants was relative small. Second, the observational 
design of the study identifies only an association and not cau-
sality. Moreover, due to the observational design, only single 
measurements were available. Third, data regarding angio-
tensin converting enzyme inhibitor or angiotensin II receptor 
blocker use that may display anti-inflammatory effects are 
missing. Finally, we have to acknowledge that paroxysmal AF 
patients are a quite heterogeneous group in terms of symptoms 
and arrhythmia burden, and thus the relative impact on γ-GT 
and ALT levels may be different. 
C l i n i C A l  i M P l i C A T i o n S
Several issues regarding the role of oxidative stress 
in AF remain to be elucidated. Up to now, it is not clear 
whether oxidative stress is a primary pathogenetic event or 
a consequence of AF. However, there is a possibility that 
both processes feeding each other leading to a vicious cycle. 
Even though recent studies point to enzymatic sources of 
ROS and to molecular targets of oxidative damage, the ex-
act pathophysiologic mechanisms have not been adequately 
investigated. The implementation of interventions targeting 
selectively at these specific pathways would be the ideal mode 
of studying these phenomena leading to the development of 
effective therapeutic strategies. Factors that reduce oxidative 
stress in cardiovascular diseases have not yet been tested in 
the setting of AF. These include xanthine oxidase inhibitors 
such as allopurinol, thiol-containing compounds such as N-
acetylcysteine and α-lipoic acid, selective NAD(P)H oxidase 
inhibitors (experimental agents), as well as experimental gene 
transfer strategies aiming at overexpression of edogenous 
antioxidant enzymes. 
C o n C l u S i o n 
This observational study shows for the first time an as-
sociation between increased levels within normal reference 
intervals of γ-GT and of ALT and AF. Serum γ-GT levels may 
be additionally related to the burden of AF. Larger studies are 
needed to validate our findings.
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